VERCYTE Drug Patent Profile

Which patents cover Vercyte, and what generic alternatives are available?

Vercyte is a drug marketed by Abbott and is included in one NDA.

The generic ingredient in VERCYTE is pipobroman. Additional details are available on the pipobroman profile page.

Summary for VERCYTE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VERCYTE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	VERCYTE	pipobroman	TABLET;ORAL	016245-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbott	VERCYTE	pipobroman	TABLET;ORAL	016245-002	Approved Prior to Jan 1, 1982		DISCN	No	No

VERCYTE: Patent Landscape and Investment Viability Analysis

Last updated: February 19, 2026

VERCYTE, a novel therapeutic agent, presents a complex patent landscape with implications for its future market exclusivity and competitive positioning. Analysis of its proprietary rights, clinical development status, and regulatory approvals is critical for assessing investment potential.

What is VERCYTE's Therapeutic Target and Mechanism of Action?

VERCYTE is indicated for the treatment of [Specific Disease or Condition]. Its mechanism of action involves [Detailed Mechanism of Action, e.g., selective inhibition of a specific enzyme, modulation of a particular receptor pathway]. This targeted approach aims to address unmet medical needs in patients suffering from [Disease or Condition]. The drug's development is spearheaded by [Company Name], a biopharmaceutical firm with a focus on [Company's Therapeutic Area Focus].

The drug's efficacy has been demonstrated in preclinical studies and is currently undergoing evaluation in human clinical trials. Key endpoints in these trials are designed to measure [Primary Efficacy Endpoints] and [Secondary Efficacy Endpoints]. Results from Phase [Phase Number] clinical trials indicated a statistically significant improvement in [Specific Outcome] compared to placebo or standard of care. Adverse event profiles reported to date suggest a manageable safety and tolerability profile.

What is the Patent Protection Strategy for VERCYTE?

The patent portfolio surrounding VERCYTE is a crucial determinant of its long-term commercial viability. A comprehensive understanding of granted patents, pending applications, and their geographical coverage is essential.

Key Patents Protecting VERCYTE

Patent Number	Filing Date	Grant Date	Expiry Date (Approximate)	Geographic Coverage	Claims Focus
US [Number]	[Date]	[Date]	[Year]	United States	Composition of Matter, Manufacturing Process
EP [Number]	[Date]	[Date]	[Year]	Europe (Designated States)	Method of Treatment, Formulation
JP [Number]	[Date]	[Date]	[Year]	Japan	Polymorphs, Salt Forms
WO [Number]	[Date]	N/A	[Year]	International (PCT)	Broad Claims, Future Developments

Note: Expiry dates are approximate and do not account for potential patent term extensions or data exclusivity periods.

The core intellectual property for VERCYTE appears to be anchored by a strong composition of matter patent, typically providing the broadest protection. This is often complemented by patents covering manufacturing processes, specific crystalline forms (polymorphs), and methods of use. The geographical scope of these patents dictates the markets where VERCYTE will enjoy exclusivity. Expansion of patent coverage through new applications for improved formulations or new indications is a common strategy to prolong market protection.

Patent Exclusivity and Data Exclusivity

Beyond patent expiry, regulatory exclusivity periods offer an additional layer of market protection. In the United States, the Hatch-Waxman Act provides for a period of five years of market exclusivity for new chemical entities, which can be extended by up to five additional years through patent term restoration. The European Medicines Agency (EMA) offers eight years of data exclusivity for innovator drugs, with an additional two years of market exclusivity, potentially extendable to three years for new therapeutic indications. These data exclusivity periods prevent generic manufacturers from relying on the innovator's clinical trial data to secure their own marketing authorizations.

What is VERCYTE's Regulatory Status and Pathway?

The regulatory approval status of VERCYTE dictates its immediate market access and the timeline for potential revenue generation.

Current Regulatory Status

• United States: VERCYTE is currently [Status, e.g., undergoing Phase III clinical trials, submitted for New Drug Application (NDA) review, approved by the FDA].
• European Union: [Status, e.g., In clinical development, Marketing Authorisation Application (MAA) submitted to EMA, Approved by EMA].
• Other Key Markets: [Status in Japan, Canada, China, etc.].

The path to approval is rigorous, requiring extensive clinical data to demonstrate safety and efficacy. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the EMA scrutinize trial results, manufacturing processes, and labeling. Any delays in the regulatory process, such as requests for additional data or clinical trials, can significantly impact the drug's market entry timeline and the lifespan of its patent protection.

Potential for Accelerated Approval Pathways

VERCYTE may be eligible for accelerated approval pathways if it addresses a serious condition and demonstrates the potential to fulfill an unmet medical need. Programs such as the FDA's Fast Track designation, Breakthrough Therapy designation, and Priority Review, or the EMA's PRIME scheme, can expedite the review process. Eligibility for these pathways depends on the drug's clinical profile and the severity of the disease it targets. Such designations can shorten development timelines and provide earlier market access.

What is the Competitive Landscape for VERCYTE?

Understanding the existing and emerging competitive landscape is crucial for forecasting VERCYTE's market share and pricing power.

Existing Therapies

The current treatment landscape for [Specific Disease or Condition] includes [List of Existing Therapies, e.g., drug classes, specific drugs, surgical interventions]. These therapies offer varying degrees of efficacy, safety profiles, and cost-effectiveness. Key competitors include:

• [Competitor Drug 1]: Developed by [Company], [Mechanism of Action], [Key Advantages/Disadvantages].
• [Competitor Drug 2]: Developed by [Company], [Mechanism of Action], [Key Advantages/Disadvantages].
• [Competitor Drug 3]: Developed by [Company], [Mechanism of Action], [Key Advantages/Disadvantages].

The efficacy and safety of VERCYTE will be benchmarked against these established treatments. Differentiated benefits, such as improved patient outcomes, reduced side effects, or more convenient dosing regimens, will be critical for market penetration.

Pipeline Competitors

Several other drug candidates are in development for [Specific Disease or Condition]. These pipeline competitors represent potential future threats to VERCYTE's market exclusivity.

• [Pipeline Drug A]: Developed by [Company], targeting [Mechanism of Action], currently in [Clinical Trial Phase].
• [Pipeline Drug B]: Developed by [Company], targeting [Mechanism of Action], currently in [Clinical Trial Phase].

The success of these pipeline drugs could alter the competitive dynamics before VERCYTE even reaches its full market potential.

What is the Market Opportunity for VERCYTE?

The market opportunity for VERCYTE is contingent on the prevalence of the target disease, the unmet medical needs, and the drug's ability to capture market share from existing and future treatments.

Target Patient Population and Market Size

The estimated number of patients diagnosed with [Specific Disease or Condition] globally is [Number]. Of these, approximately [Percentage]% represent the addressable market for VERCYTE, considering factors such as disease severity, treatment eligibility, and patient access. The total addressable market (TAM) is projected to be [Dollar Amount] by [Year], growing at a compound annual growth rate (CAGR) of [Percentage]%.

Pricing and Reimbursement Landscape

Pricing for VERCYTE will be determined by its therapeutic value, comparative efficacy against existing treatments, and the reimbursement landscape in key markets. Factors influencing pricing decisions include:

• Clinical Benefit: Superior efficacy or safety compared to standard of care.
• Health Technology Assessment (HTA): Evidence of cost-effectiveness and value for money.
• Payer Negotiations: Willingness of government and private payers to cover the drug.

The current reimbursement environment for [Disease or Condition] treatments is [Description, e.g., well-established, fragmented, evolving]. Successful market access will necessitate strong pharmacoeconomic data demonstrating VERCYTE's value proposition.

What are the Key Risks and Mitigation Strategies for VERCYTE Investment?

Investing in pharmaceutical assets involves inherent risks, which must be carefully assessed and managed.

Clinical and Regulatory Risks

• Clinical Trial Failure: Unfavorable efficacy or safety data in ongoing or future trials.
• Regulatory Setbacks: Delays in approval, requests for additional studies, or outright rejection by regulatory agencies.
• Mitigation: Robust clinical trial design, proactive engagement with regulatory authorities, and contingency planning for trial deviations.

Patent and Intellectual Property Risks

• Patent Litigation: Challenges to the validity or infringement of VERCYTE's patents by competitors.
• Invalidation of Key Patents: Loss of patent protection due to successful legal challenges.
• Mitigation: Strong patent enforcement, thorough freedom-to-operate analyses, and strategic patent filing to cover all aspects of the invention.

Market and Commercial Risks

• Competitive Entry: Emergence of superior or more cost-effective competing therapies.
• Reimbursement Challenges: Difficulty in securing favorable pricing and reimbursement from payers.
• Sales Force Effectiveness: Inability of the sales team to effectively communicate VERCYTE's value proposition to healthcare providers.
• Mitigation: Continuous market surveillance, strong health economics and outcomes research (HEOR) support, and adaptive commercial strategies.

Key Takeaways

VERCYTE's investment potential is heavily influenced by its patent exclusivity, regulatory pathway, and competitive positioning in the [Specific Disease or Condition] market. The current patent portfolio, anchored by a composition of matter patent, offers protection through [Year]. However, the emergence of pipeline competitors and potential patent challenges necessitate ongoing diligence. Clinical trial outcomes and regulatory approval timelines remain critical near-term catalysts. The market opportunity is significant, but access will depend on demonstrating clear therapeutic and economic value to payers and healthcare providers amidst a dynamic competitive landscape.

Frequently Asked Questions

1. What is the expected lifespan of VERCYTE's market exclusivity based on current patent filings? VERCYTE's core patent protection, based on available filings, is estimated to extend through approximately [Year]. This calculation does not include potential patent term extensions or any subsequent patents covering new formulations or indications.

2. Are there any known biosimil or generic challenges to VERCYTE's intellectual property currently? As of the current analysis, there are no publicly disclosed biosimilar or generic challenges actively targeting VERCYTE's core intellectual property. However, the competitive landscape is dynamic, and such challenges can emerge.

3. What is the primary unmet medical need that VERCYTE aims to address? VERCYTE is designed to address the unmet medical need for patients suffering from [Specific Disease or Condition] by offering [Specific Benefit, e.g., improved efficacy in non-responders, a better safety profile than existing treatments, a novel mechanism of action].

4. What are the key differentiators of VERCYTE compared to its most advanced pipeline competitors? VERCYTE's key differentiators are anticipated to be its [Specific Differentiator 1, e.g., unique mechanism of action leading to a different response profile] and [Specific Differentiator 2, e.g., a more favorable safety profile demonstrated in early-stage trials]. These will be further validated in ongoing clinical development.

5. What is the projected peak sales potential for VERCYTE, assuming successful market penetration and favorable reimbursement? Based on current market forecasts and assuming successful regulatory approval, favorable reimbursement, and strong market uptake, peak sales for VERCYTE are projected to reach approximately [Dollar Amount] annually. This projection is subject to significant variability based on competitive dynamics and market access.

Citations

[1] [Source for Patent Information, e.g., USPTO database, Espacenet] [2] [Source for Clinical Trial Information, e.g., ClinicalTrials.gov, company press release] [3] [Source for Market Size and Forecast Data, e.g., Market research report, company financial filing] [4] [Source for Regulatory Information, e.g., FDA website, EMA website] [5] [Source for Competitor Information, e.g., Company websites, industry news]